Volumen: 18 # Number : 3
Publication Date : Septiembre - Diciembre Year: 2014
Ibrutinib. Potent inhibitor
Authors: Caffaro M J
Abstract: Ibrutinib is an oral potent inhibitor of the BTK enzyme.
Ibrutinib treatment inhibits numerous process including
BCR signaling pathways, B cells proliferation, migration
and survival. In Ibrutinib monotherapy was associated
with durable remissions in patients with relapsed and refractory
CLL, including patients with high risk genetic
lesions and patients with relapsed and refractory mantle-
cell lymphoma. The favorable toxicity profile suggest
that Ibrutinib provides the opportunity for treatment with
less intensive and more effective regimens than those currently
available.
Key words: Ibrutinib,
Bruton´s tyrosine kinase inhibitor,
B cell receptor,
CLL,
Mantle-cell lymphoma.
Pages :
|
